Strategic Financial Concepts LLC Acquires Shares of 46,655 TG Therapeutics, Inc. (NASDAQ:TGTX)

Strategic Financial Concepts LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 46,655 shares of the biopharmaceutical company's stock, valued at approximately $1,404,000.

A number of other institutional investors and hedge funds also recently modified their holdings of TGTX. Valeo Financial Advisors LLC raised its holdings in shares of TG Therapeutics by 32.4% during the fourth quarter. Valeo Financial Advisors LLC now owns 13,532 shares of the biopharmaceutical company's stock worth $407,000 after acquiring an additional 3,309 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares in the last quarter. New York State Teachers Retirement System raised its holdings in shares of TG Therapeutics by 1.9% during the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock worth $1,317,000 after acquiring an additional 837 shares in the last quarter. Castellan Group purchased a new stake in shares of TG Therapeutics during the fourth quarter worth $8,539,000. Finally, Van ECK Associates Corp purchased a new stake in shares of TG Therapeutics during the fourth quarter worth $4,219,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TGTX shares. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price on the stock. StockNews.com lowered TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded down $0.06 during trading on Friday, reaching $30.88. The company's stock had a trading volume of 1,659,954 shares, compared to its average volume of 1,631,928. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business's fifty day moving average price is $31.07 and its 200-day moving average price is $27.78. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of -308.77 and a beta of 2.26. TG Therapeutics, Inc. has a one year low of $12.90 and a one year high of $36.84.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.